Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Clinician in protective gloves holding a BCG (tuberculosis) vaccine vial.
BCG vaccination increased the risk of symptomatic disease during the first six months following enrollment in the trial and did not reduce the incidence of COVID-19 in participants.
iStock, SyhinStas

BCG Vaccine Ineffective Against COVID-19 in Health Care Workers

The trial remains valuable for future research despite the unclear results

Germans Trias i Pujol Research Institute (IGTP)
Published:Jun 12, 2023
|3 min read
Register for free to listen to this article
Listen with Speechify

The Bacillus Calmette-Guerin (BCG) vaccine, primarily developed to prevent tuberculosis, is administered to over 130 million babies worldwide each year. Despite some studies suggesting that BCG may enhance immunity against other respiratory infections in adolescents and adults, the WHO did not endorse its use for COVID-19 at the onset of the pandemic, citing a lack of evidence regarding its efficacy. 

To address this uncertainty, the BRACE trial was started in March 2020 to test the efficacy of the BCG vaccine in protecting against COVID-19, at a time when no vaccines specifically for this viral strain were available.

The BRACE trial

This double-blind, placebo-controlled trial involved 3,988 healthcare workers, a highly exposed group, across 36 centers and hospitals in Australia, Brazil, the UK, the Netherlands, and Spain. It was led by the Murdoch Children's Research Institute (MCRI) in Melbourne and brought to Europe with the support of the Bill & Melinda Gates Foundation and coordinated by the University Medical Centre (UMC) in Utrecht.

In fall of 2020, the Germans Trias i Pujol University Hospital (HUGTiP), along with five other Spanish hospitals, joined the clinical trial. This Can Ruti institution contributed 46 participants who underwent regular check-ups every three months, with a survey and a blood sample collection. The final visits concluded in July 2021, marking the end of a 12-month follow-up period which was adhered to by 95 percent of the participants.

“This is a large size, international trial that highlights the importance of testing proposed interventions through carefully designed randomized trials, even in the midst of a pandemic. The hypothesis was worth to be evaluated in such a critical situation while maintaining a rigorous methodology. The setting-up was quite challenging, spanning five countries across three continents. Both the data and samples collected are very important in terms of allowing a better understanding of BCG response," explains Cristina Prat-Aymerich, MD, PhD, co-leader of an IGTP research group dedicated to tuberculosis and head of the respiratory and mycobacterial infection section in the Microbiology service at HUGTiP, currently working in UMC Utrecht, the Netherlands.

BCG vaccine did not reduce COVID-19 risk

A recent study published in The New England Journal of Medicine analyzes the results of the second stage of the trial. Researchers found that BCG vaccination did not reduce the incidence of COVID-19. In fact, it increased the risk of symptomatic disease during the first six months following enrollment in the trial, which was 14.7 percent in the BCG group compared to 12.3 percent in the placebo group, a difference deemed not statistically significant.

The increase in symptomatic COVID-19 among those vaccinated with BCG could possibly be due to a stronger immune response to the virus, but it is unclear whether this had any impact on protection against severe cases or reinfections. Interestingly, older participants who were vaccinated had shorter illness durations, hinting at potentially more efficient virus clearance.

Unclear: Protection against life-threatening COVID-19

Recruitment for the trial was stopped prematurely and the follow-up period was reduced, which affected the number of episodes recorded. Consequently, the lack of significant difference between the studied groups could be caused by the trial not being powerful enough to detect a real effect—possibly a type II error.

Antoni Rosell, MD, PhD, clinical director of the Thorax Institute at HUGTiP, states that "very few people in the trial were hospitalized or died, so the trial could not test whether BCG reduced the risk of severe types of COVID-19. This is partly due to the earlier-than-expected availability of COVID-19 vaccines (with health care workers prioritized) leading to recruitment stopping before the target number was reached as well as shorter follow-up period."

Although the BCG vaccine did not protect against symptomatic COVID-19, this research provides valuable insights into the immune response to the virus and the potential benefits and drawbacks of repurposing existing vaccines. 

José Domínguez, PhD, co-leader of an IGTP research group, is positive about the future. "There remains strong evidence that BCG protects against tuberculosis and has important beneficial effects against other infections in infants. The trial allowed to further explore the safety of revaccination in adults and soon will be reported whether BCG protected against infections other than SARS-CoV-2."

The BRACE Trial Consortium Group will continue to analyze data and will share further results on the impact of the BCG vaccine on other infections and the effect on COVID-19 vaccine responses later this year.

- This press release was originally published on the Germans Trias i Pujol Research Institute (IGTP) website